Based on the obtained data, the significant factor in the prediction of response to therapy was the liraglutide dose (3.0 mg/day, dose-dependent efficacy), and for patients with obesity, the significant factor was baseline GLP-1 level in the blood (>2.15 ng/ml). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.